"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Descriptor ID |
D011565
|
| MeSH Number(s) |
C17.800.859.675
|
| Concept/Terms |
Pustulosis of Palms and Soles- Pustulosis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
|
Below are MeSH descriptors whose meaning is more general than "Psoriasis".
Below are MeSH descriptors whose meaning is more specific than "Psoriasis".
This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 3 | 4 |
| 1999 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 8 | 0 | 8 |
| 2004 | 4 | 0 | 4 |
| 2005 | 9 | 0 | 9 |
| 2006 | 10 | 0 | 10 |
| 2007 | 9 | 0 | 9 |
| 2008 | 10 | 1 | 11 |
| 2009 | 7 | 1 | 8 |
| 2010 | 8 | 1 | 9 |
| 2011 | 8 | 1 | 9 |
| 2012 | 6 | 2 | 8 |
| 2013 | 7 | 0 | 7 |
| 2014 | 8 | 0 | 8 |
| 2015 | 5 | 1 | 6 |
| 2016 | 12 | 1 | 13 |
| 2017 | 14 | 0 | 14 |
| 2018 | 22 | 0 | 22 |
| 2019 | 14 | 0 | 14 |
| 2020 | 13 | 1 | 14 |
| 2021 | 8 | 0 | 8 |
| 2022 | 7 | 0 | 7 |
| 2023 | 7 | 0 | 7 |
| 2024 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Psoriasis" by people in Profiles.
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am J Clin Dermatol. 2024 Sep; 25(5):795-810.
-
Active biointegrated living electronics for managing inflammation. Science. 2024 May 31; 384(6699):1023-1030.
-
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024 May 29; 120(7):678-680.
-
Bimekizumab for the treatment of psoriasis. Immunotherapy. 2024 04; 16(7):431-446.
-
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 03 15; 190(4):477-485.
-
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Aug; 38(8):1543-1554.
-
Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. 2024 Jun; 90(6):1271-1275.
-
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024 02 01; 160(2):204-209.
-
The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases. Adv Ther. 2023 11; 40(11):5090-5101.
-
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 10 28; 402(10412):1541-1551.